NeurAxis (NASDAQ:NRXS – Get Free Report) and Helius Medical Technologies (NASDAQ:HSDT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Profitability
This table compares NeurAxis and Helius Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeurAxis | -594.55% | N/A | -899.27% |
| Helius Medical Technologies | -1,374.22% | -221.11% | -86.23% |
Institutional & Insider Ownership
11.8% of NeurAxis shares are held by institutional investors. Comparatively, 18.6% of Helius Medical Technologies shares are held by institutional investors. 7.3% of Helius Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
| Helius Medical Technologies | 0 | 0 | 1 | 0 | 3.00 |
Helius Medical Technologies has a consensus target price of $54.50, suggesting a potential upside of 1,012.24%. Given Helius Medical Technologies’ higher probable upside, analysts clearly believe Helius Medical Technologies is more favorable than NeurAxis.
Earnings and Valuation
This table compares NeurAxis and Helius Medical Technologies’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeurAxis | $2.46 million | 7.55 | -$14.63 million | ($4.59) | -0.61 |
| Helius Medical Technologies | $640,000.00 | 6.81 | -$8.85 million | ($14.46) | -0.34 |
Helius Medical Technologies has lower revenue, but higher earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Helius Medical Technologies beats NeurAxis on 6 of the 11 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About Helius Medical Technologies
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
